Merck KGaAWBO:MRCK +5.22%78 Net Margin % is 12.84% as of Mar. 2026, which is 3% below its 10-year median of 13.29. GuruFocus rates WBO:MRCK with a GF Score™ of 78/100 and a GF Value™ of €140.65 (Fairly Valued). The stock has 9 warning signs investors should review. Among 956 Drug Manufacturers companies, Merck KGaA ranks better than 70.61% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Merck KGaA's Net Income for the
three
months ended in Mar. 2026 was €659 Mil. Merck KGaA's Revenue for the
three
months ended in Mar. 2026 was €5,134 Mil. Therefore, Merck KGaA's net margin for the quarter that ended in Mar. 2026 was 12.84%.
The historical rank and industry rank for Merck KGaA's Net Margin % or its related term are showing as below:
WBO:MRCK'
s Net Margin % Range Over the Past 10 Years
Min: 8.17 Med: 13.29 Max: 22.74
Current: 12.08
WBO:MRCK's Net Margin % is ranked better than 70.61% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs WBO:MRCK: 12.08
Merck KGaA (WBO:MRCK) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Merck KGaA Net Margin % Related Terms
Merck KGaA Net Margin % Historical Data
* Premium members only.
The historical data trend for Merck KGaA's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:MRCK vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Merck KGaA's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Merck KGaA Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Merck KGaA's Net Margin % distribution charts can be found below:
* The bar in red indicates where Merck KGaA's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Merck KGaA (WBO:MRCK) has a Net Margin % of 12.84% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Merck KGaA and its competitors. This is near median its historical median of 13.29. Over the past decade, Merck KGaA's Net Margin % has ranged from 8.17 to 22.74. According to the industry distribution chart, Merck KGaA ranks #281 out of 956 companies in the Drug Manufacturers industry, placing it in the top 29.4%.
Is Merck KGaA's Net Margin % too high?
Merck KGaA's current Net Margin % of 12.84% is near median its 10-year median of 13.29. Over the past 10 years, this metric has ranged from a low of 8.17 to a high of 22.74. The Drug Manufacturers industry median Net Margin % is 5.56. Merck KGaA's value of 12.84% is 130.9% above this industry median. Based on the distribution chart, Merck KGaA ranks #281 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Merck KGaA has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Merck KGaA's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Merck KGaA ranks #281 out of 956 companies for Net Margin %. This puts Merck KGaA in the upper half of its industry. The industry median Net Margin % is 5.56. Merck KGaA's value of 12.84% is 130.9% above this benchmark. Historically, Merck KGaA's own Net Margin % has ranged from 8.17 to 22.74 over the past decade. While the company's 10-year median is 13.29 vs. the industry median of 5.56, Merck KGaA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Merck KGaA's current Net Margin % of 12.84% is 130.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Merck KGaA and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Merck KGaA's current Net Margin % is 12.84%, which is near median its own 10-year median of 13.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck KGaA stock overvalued right now?
Based on GuruFocus' analysis, Merck KGaA (WBO:MRCK) is currently considered Fairly Valued. The stock's GF Value™ is €140.65, compared to a current price of €147.15 — trading 4.6% above its estimated fair value. The current Net Margin % is 12.84%, which is near median its 10-year median of 13.29 and 130.9% above the Drug Manufacturers industry median of 5.56. Merck KGaA's overall GF Score™ is 78/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Merck KGaA (WBO:MRCK), the current Net Margin % is 12.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Merck KGaA (WBO:MRCK) Overvalued in 2026?
Based on GuruFocus' analysis, Merck KGaA stock appears to be overvalued.
The current stock price of €147.15 is trading 4.6% above its estimated GF Value™ of €140.65.
GuruFocus considers Merck KGaA to be Fairly Valued.
Key valuation signals for WBO:MRCK:
Net Margin %: 12.84% (near median its 10-year median of 13.29)
GF Value™: €140.65 vs. price of €147.15 (4.6% above fair value)
Industry Position: 130.9% above the Drug Manufacturers median (#281 of 956)
No single metric tells the full story. See the WBO:MRCK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
78GF Score
Get the complete analysis for WBO:MRCK
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:MRCK has been successfully added to your 
